Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 17;12(1):5.
doi: 10.1186/1477-5956-12-5.

Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics

Fei Song, Anne Poljak  1 , Nicole A Kochan, Mark Raftery, Henry Brodaty, George A Smythe, Perminder S Sachdev
Affiliations

Plasma protein profiling of Mild Cognitive Impairment and Alzheimer's disease using iTRAQ quantitative proteomics

Fei Song et al. Proteome Sci. .

Abstract

Background: With the promise of disease modifying treatments, there is a need for more specific diagnosis and prognosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Plasma biomarkers are likely to be utilised to increase diagnostic accuracy and specificity of AD and cognitive decline.

Methods: Isobaric tags (iTRAQ) and proteomic methods were used to identify potential plasma biomarkers of MCI and AD. Relative protein expression level changes were quantified in plasma of 411 cognitively normal subjects, 19 AD patients and 261 MCI patients. Plasma was pooled into 4 groups including normal control, AD, amnestic single and multiple domain MCI (aMCI), and nonamnestic single and multiple domain MCI (nMCI). Western-blotting was used to validate iTRAQ data. Integrated function and protein interactions were explored using WEB based bioinformatics tools (DAVID v6.7 and STRING v9.0).

Results: In at least two iTRAQ replicate experiments, 30 proteins were significantly dysregulated in MCI and AD plasma, relative to controls. These proteins included ApoA1, ApoB100, complement C3, C4b-binding protein, afamin, vitamin D-binding protein precursor, isoform 1 of Gelsolin actin regulator, Ig mμ chain C region (IGHM), histidine-rich glycoprotein and fibrinogen β and γ chains. Western-blotting confirmed that afamin was decreased and IGHM was increased in MCI and AD groups. Bioinformatics results indicated that these dysregulated proteins represented a diversity of biological processes, including acute inflammatory response, cholesterol transport and blood coagulation.

Conclusion: These findings demonstrate that expression level changes in multiple proteins are observed in MCI and AD plasma. Some of these, such as afamin and IGHM, may be candidate biomarkers for AD and the predementia condition of MCI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Association networks of dysregulated proteins using STRING v9.0.
Figure 2
Figure 2
Comparison of western blot analysis and iTRAQ results for IGHM.
Figure 3
Figure 3
Comparison of western blot analysis and iTRAQ results for afamin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kelley BJ, Petersen RC. Alzheimer’s disease and mild cognitive impairment. Neurol Clin. 2007;25:577–609. doi: 10.1016/j.ncl.2007.03.008. - DOI - PMC - PubMed
    1. Rosenberg PB, Lyketsos C. Mild cognitive impairment: searching for the prodrome of Alzheimer’s disease. World Psychiatry. 2008;7:72–78. - PMC - PubMed
    1. Liao P-c, Yu L, Kuo C-C, Lin C, Kuo Y-M. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer’s disease. Proteomics Clin Appl. 2007;1:506–512. doi: 10.1002/prca.200600684. - DOI - PubMed
    1. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S. et al.Proteome-based plasma biomarkers for Alzheimer’s disease. Brain. 2006;129:3042–3050. doi: 10.1093/brain/awl279. - DOI - PubMed
    1. Cutler P, Akuffo E, Briggs D, Bodnar W, Debouck C, Fox S, Bibson R, Gormley D, Holbrook J, Hunter A. et al.Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer’s disease in human plasma. Proteomics Clin Appl. 2008;2:467–477. doi: 10.1002/prca.200780101. - DOI - PubMed